uniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore
· seekingalpha.com
Analyst sees uniQure's (QURE) AMT-130 as a potential Huntington’s treatment: high-dose therapy slowed cUHDRS decline 80% at 3 years.
Editor's note: Seeking Alpha is proud to welcome Biotech Fundamentals as a new contributing analyst. You can become one too! Share your best investment idea by ...